Congenia Overview

  • Year Founded
  • 2004

Year Founded

  • Status
  • Out of Business

  • Latest Deal Type
  • Out of Business

Congenia General Information

Description

Developer of biopharmaceutical drugs designed to target the mitochondrial permeability transition pore.The company's drugs are focused on developing inhibitors to stop the mitochondrial permeability transition that can lead to cell death, enabling patients and medical practitioners to clinically validate the pathogenesis of several diseases and other indications.

Contact Information

Website
www.congenia.it
Ownership Status
Out of Business
Financing Status
Formerly VC-backed
Corporate Office
  • Via Privata Giovannino De Grassi, 11
  • 20123 Milan
  • Italy
+39 02
Primary Industry
Drug Discovery
Other Industries
Drug Delivery
Biotechnology
Vertical(s)
Life Sciences
Corporate Office
  • Via Privata Giovannino De Grassi, 11
  • 20123 Milan
  • Italy
+39 02

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Congenia Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
2. Out of Business 18-Jun-2021 Completed Out of Business
1. Buyout/LBO Completed Startup
To view Congenia’s complete valuation and funding history, request access »

Congenia Patents

  • 43

    Total Documents Applications and Grants

  • Total Patents Families

  • 15

    Granted

  • 5

    Pending

  • Expiring in next 12 mo

Congenia Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-20130245019-A1 Acrylomido derivatives useful as inhibitors of the mitochondrial permeability transition Active 27-Oct-2008
US-20110195977-A1 Acrylamido derivatives useful as inhibitors of the mitochondrial permeability transition Active 27-Oct-2008
EP-2349982-B1 Acrylamido derivatives useful as inhibitors of the mitochondrial permeability transition Active 27-Oct-2008
EP-2349982-A1 Acrylamido derivatives useful as inhibitors of the mitochondrial permeability transition Active 27-Oct-2008
AU-2009309378-A1 Acrylamido derivatives useful as inhibitors of the mitochondrial permeability transition Active 27-Oct-2008 C07C235/38
To view Congenia’s complete patent history, request access »

Ready to get started?

Request a free trial

Congenia FAQs

  • When was Congenia founded?

    Congenia was founded in 2004.

  • Who is the founder of Congenia?

    Marco Giorgio Ph.D, Paolo Bernardi, Pier Pelicci Ph.D, and Saverio Minucci are the founders of Congenia.

  • Where is Congenia headquartered?

    Congenia is headquartered in Milan, Italy.

  • What industry is Congenia in?

    Congenia’s primary industry is Drug Discovery.

  • Is Congenia a private or public company?

    Congenia is a Private company.

  • What is Congenia’s current revenue?

    The current revenue for Congenia is .

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »